NASDAQ$ETNB
89Bio Inc · Q3 2022 earnings
Q3 2022 earnings · · Investor relations
Briefing
89Bio reported financial results for Q3 2022 and provided a corporate update.
89bio reported a net loss of $26.8 million for the third quarter ended September 30, 2022. The company's cash, cash equivalents, and short-term investments totaled $193.3 million as of September 30, 2022. Enrollment was completed in the ENLIVEN Phase 2b NASH trial, with topline data expected in Q1 2023.
- Completed enrollment in ENLIVEN Phase 2b NASH trial with topline data expected in the first quarter of 2023.
- Presented additional post-hoc exploratory analyses from the Phase 1b/2a NASH study of pegozafermin at AASLD The Liver Meeting® 2022.
- Reported additional positive data from ENTRIGUE Phase 2 trial of pegozafermin in severe hypertriglyceridemia patients at European Society of Cardiology Congress 2022.
- Initiation of Phase 3 trial of pegozafermin in SHTG patients expected in the first half of 2023.
Headline financials
Revenue & EPS history
89Bio · Revenue · Quarterly
$0
Forward guidance
89bio anticipates several milestones, including topline data from the ENLIVEN Phase 2b trial in Q1 2023 and initiation of a Phase 3 trial in SHTG in the first half of 2023.
Tailwinds
- Pegozafermin has therapeutic potential and clinical benefits.
- Pegozafermin has a positive clinical benefit, safety and tolerability profile.
- Phase 2b ENLIVEN trial is underway.
- Topline data for the ENLIVEN trial is expected.
- Phase 3 trial in SHTG is expected to be initiated.
Headwinds
- The timing and outcome of the Phase 2b ENLIVEN trial in NASH are uncertain.
- The timing of topline data is uncertain.
- The initiation of the Phase 3 trial in SHTG is uncertain.
- 89bio's ability to execute on its strategy is not guaranteed.
- Positive results from a clinical study may not be predictive of future results.
Historical earnings impact
How earnings announcements have historically affected this stock's price.
Avg. return before/after earnings
Based on 7 quarterly earnings reports
-0.1%
Avg return
Earnings day
-4.6%
Avg return
5 days after
-2.8%
Avg return
30 days after
54%
13 / 24 earnings
Positive
+14.8%
Q4 2019
Best reaction
-19.4%
Q1 2021
Worst reaction
| Quarter | Report date | Reaction (Day 0) | +5 days | +30 days |
|---|---|---|---|---|
| Q3 2025 | — | — | — | |
| Q2 2025 | +1.7% | +1.3% | -1.7% | |
| Q1 2025 | -3.7% | -4.1% | +18.6% | |
| Q4 2024 | -1.0% | -7.1% | -3.7% | |
| Q3 2024 | +2.8% | -10.9% | -20.6% | |
| Q2 2024 | -10.9% | -11.8% | -0.9% | |
| Q1 2024 | -3.5% | +0.8% | -10.2% | |
| Q4 2023 | +7.3% | -0.2% | -1.3% | |
| Q3 2023 | -11.8% | — | — | |
| Q2 2023 | +5.3% | — | — | |
| Q1 2023 | +1.3% | — | — | |
| Q4 2022 | -1.1% | — | — | |
| Q3 2022 | +14.2% | — | — | |
| Q2 2022 | +3.6% | — | — | |
| Q1 2022 | +14.6% | — | — | |
| Q4 2021 | +5.1% | — | — | |
| Q3 2021 | +1.4% | — | — | |
| Q2 2021 | +1.1% | — | — | |
| Q1 2021 | -19.4% | — | — | |
| Q4 2020 | -4.7% | — | — | |
| Q3 2020 | -0.8% | — | — | |
| Q2 2020 | +1.6% | — | — | |
| Q1 2020 | -6.2% | — | — | |
| Q4 2019 | +14.8% | — | — | |
| Q3 2019 | -13.5% | — | — | |
| Q2 2019 | — | — | — | |
| Q1 2019 | — | — | — | |
| Q4 2018 | — | — | — | |
| Q3 2018 | — | — | — |
Discussion
Share your read of this quarter. Sign-in carries your eToro identity.
Join the conversation
Sign in with eToro to post your read of this quarter and vote on others'.
Sign in with eToro